Dataset Information

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.

ABSTRACT:

Background

The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting.

Methods

We conducted a test-negative case-control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a positive polymerase-chain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19-like symptom. Controls were defined on the basis of a negative PCR test for SARS-CoV-2, regardless of symptoms, and were matched to cases according to the week of the test date and site. Using conditional logistic regression with adjustment for age, race and ethnic group, underlying conditions, and exposures to persons with Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days after receipt of the first dose through 6 days after receipt of the second dose) and complete vaccination (assessed ≥7 days after receipt of the second dose).

Results

The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer-BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or ≥50 years), race and ethnic group, presence of underlying conditions, and level of patient contact. Estimates of vaccine effectiveness were lower during weeks 9 through 14 than during weeks 3 through 8 after receipt of the second dose, but confidence intervals overlapped widely.

Conclusions

The BNT162b2 and mRNA-1273 vaccines were highly effective under real-world conditions in preventing symptomatic Covid-19 in health care personnel, including those at risk for severe Covid-19 and those in racial and ethnic groups that have been disproportionately affected by the pandemic. (Funded by the Centers for Disease Control and Prevention.).

SUBMITTER: Pilishvili T

PROVIDER: S-EPMC8482809 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.

Pilishvili Tamara T Gierke Ryan R Fleming-Dutra Katherine E KE Farrar Jennifer L JL Mohr Nicholas M NM Talan David A DA Krishnadasan Anusha A Harland Karisa K KK Smithline Howard A HA Hou Peter C PC Lee Lilly C LC Lim Stephen C SC Moran Gregory J GJ Krebs Elizabeth E Steele Mark T MT Beiser David G DG Faine Brett B Haran John P JP Nandi Utsav U Schrading Walter A WA Chinnock Brian B Henning Daniel J DJ Lovecchio Frank F Lee Jane J Barter Devra D Brackney Monica M Fridkin Scott K SK Marceaux-Galli Kaytlynn K Lim Sarah S Phipps Erin C EC Dumyati Ghinwa G Pierce Rebecca R Markus Tiffanie M TM Anderson Deverick J DJ Debes Amanda K AK Lin Michael Y MY Mayer Jeanmarie J Kwon Jennie H JH Safdar Nasia N Fischer Marc M Singleton Rosalyn R Chea Nora N Magill Shelley S SS Verani Jennifer R JR Schrag Stephanie J SJ

The New England journal of medicine 20210922 25

<h4>Background</h4>The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting.<h4>Methods</h4>We conducted a test-negative case-control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a po ...[more]

PMID: 34551224

Similar Datasets

Project description:ImportanceSeveral COVID-19 vaccines have been authorized in the US, yet preliminary evidence suggests high levels of vaccine hesitancy and wide racial, ethnic, and socioeconomic disparities in uptake.ObjectiveTo assess COVID-19 vaccine acceptance among health care personnel (HCP) during the first 4 months of availability in a large academic hospital, compare acceptance with previously measured vaccine hesitancy, and describe racial, ethnic, and socioeconomic disparities in vaccine uptake.Design, setting, and participantsThis cross-sectional study included 12 610 HCP who were offered COVID-19 vaccination at a major academic hospital in Philadelphia between December 16, 2020, and April 16, 2021.ExposuresFor each HCP, data were collected on occupational category, age, sex, race and ethnicity (Asian or Pacific Islander, Black or African American [Black], Hispanic, White, and multiracial), and social vulnerability index (SVI) at the zip code of residence.Main outcomes and measuresVaccine uptake by HCP at the employee vaccination clinic.ResultsThe study population included 4173 men (34.8%) and 7814 women (65.2%) (623 without data). A total of 1480 were Asian or Pacific Islander (12.4%); 2563 (21.6%), Black; 452 (3.8%), Hispanic; 7086 (59.6%), White; and 192 (1.6%), multiracial; 717 had no data for race and ethnicity. The mean (SD) age was 40.9 (12.4) years, and 9573 (76.0%) received at least 1 vaccine dose during the first 4 months of vaccine availability. Adjusted for age, sex, job position, and SVI, Black (relative risk [RR], 0.69; 95% CI, 0.66-0.72) and multiracial (RR, 0.80; 95% CI, 0.73-0.89) HCP were less likely to receive vaccine compared with White HCP. When stratified by job position, Black nurses (n = 189; 62.8%), Black HCP with some patient contact (n = 466; 49.9%), and Black HCP with no patient contact (n = 636; 56.3%) all had lower vaccine uptake compared with their White and Asian or Pacific Islander counterparts. Similarly, multiracial HCP with some (n = 26; 52.0%) or no (n = 48; 58.5%) patient contact had lower vaccine uptake. In contrast, Black physicians were just as likely to receive the vaccine as physicians of other racial and ethnic groups.Conclusions and relevanceIn this cross-sectional study, more than two-thirds of HCP at a large academic hospital in Philadelphia received a COVID-19 vaccine within 4 months of vaccine availability. Although racial, ethnic, and socioeconomic disparities were seen in vaccine uptake, no such disparities were found among physicians. Better understanding of factors driving these disparities may help improve uptake.

Dataset Information

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.

Background

Methods

Results

Conclusions

Publications

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets